J. Ley

发表

Dynamic host immune response in virus-associated cancers.

Sam Q. Sun, Matthew A. Wyczalkowski, Kimberly J. Johnson, 2019 .

Dynamic host immune response in virus-associated cancers

Sam Q. Sun, Matthew A. Wyczalkowski, Kimberly J. Johnson, 2019, Communications Biology.

Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous cell carcinoma

S. El-Mofty, D. Adkins, J. Ley, 2014, Ecancermedicalscience.

Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma

Jingqin Luo, K. Trinkaus, B. Siegel, 2021, Rare tumors.

nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial

R. Paniello, W. Thorstad, H. Gay, 2021, Medical Oncology.

nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma.

K. Trinkaus, R. Paniello, W. Thorstad, 2017, Oral oncology.

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Zachary L. Skidmore, Erica K. Barnell, Katie M. Campbell, 2020, Clinical Cancer Research.

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial

Zachary L. Skidmore, Erica K. Barnell, Katie M. Campbell, 2020 .

Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck.

Y. Tao, D. Adkins, J. Ley, 2014, Oral oncology.

RTOG 0522: huge Investment in patients and resources and no benefit with addition of cetuximab to radiotherapy--why did this occur?

D. Adkins, J. Ley, L. Michel, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell Carcinoma.

P. Oppelt, J. Ley, Jared A. Cohen, 2022, Cancer journal.

Looking beyond the CRT paradigm: why induction chemotherapy is worthy of pursuit.

W. Thorstad, D. Adkins, B. Nussenbaum, 2015, Oral oncology.

T cell subtype profiling measures exhaustion and predicts anti-PD-1 response

David N. Messina, Jarret Glasscock, P. Jermann, 2022, Scientific Reports.

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.

K. Trinkaus, J. Grilley-Olson, B. V. Van Tine, 2019, The Lancet. Oncology.

Cisplatin versus Cetuximab Given Concurrently with Definitive Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

K. Trinkaus, W. Thorstad, H. Gay, 2013, Oncology.

Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

K. Trinkaus, D. Adkins, J. Lewis, 2016, Oral oncology.

Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial.

F. Worden, P. Oppelt, D. Adkins, 2021, Oral oncology.

Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial.

P. Oppelt, D. Adkins, S. Powell, 2021, Oral oncology.

Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer

I. Hagemann, P. Oppelt, D. Adkins, 2019, Medical Oncology.

Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel

P. Oppelt, D. Adkins, J. Ley, 2017, Medical Oncology.

Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.

B. Melichar, Xin Huang, C. Yen, 2021, Oral oncology.

Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).

D. Kallogjeri, A. Egloff, R. Paniello, 2021 .

Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.

K. Trinkaus, B. Siegel, P. Oppelt, 2018, The Lancet. Oncology.

Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma

L. Ding, B. V. Van Tine, D. Adkins, 2021, Oncotarget.

nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma

R. Paniello, W. Thorstad, H. Gay, 2019, Medical Oncology.

Multi-institution Analysis of Concurrent Chemoradiation Therapy With Cisplatin (CDDP) Versus Cetuximab (C225) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-HNSCC): Can HPV Help Decide Which Agent?: Definitive Management of Head-and-Neck Squamous Cell Carcinoma

N. Lee, A. Baschnagel, N. Riaz, 2014 .

Multi-institution Analysis of Concurrent Chemoradiation Therapy With Cisplatin (CDDP) Versus Cetuximab (C225) in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck (LA-HNSCC): Can HPV Help Decide Which Agent?

N. Lee, A. Baschnagel, N. Riaz, 2013 .

Impact on Health-Related Quality of Life of Induction Chemotherapy Compared With Concurrent Cisplatin and Radiation Therapy in Patients With Head and Neck Cancer.

K. Trinkaus, R. Paniello, J. Rich, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

A phase 2 trial of induction nab‐paclitaxel and cetuximab given with cisplatin and 5‐fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck

K. Trinkaus, B. Siegel, W. Thorstad, 2013, Cancer.

Multicenter phase II trial of nab-paclitaxel and cisplatin (AP) followed by chemoradiation therapy (CRT) for locally advanced head and neck squamous cell carcinoma (HNSCC).

K. Trinkaus, R. Paniello, J. Rich, 2018, Annals of Oncology.

Multicenter Phase 2 Trial of C is/Carboplatin, nAb -Paclitaxel, and C e TUX imab ( CACTUX ) as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

K. Trinkaus, P. Oppelt, D. Adkins, 2018 .

nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.

K. Trinkaus, R. Paniello, W. Thorstad, 2016, Oral oncology.

Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck

K. Trinkaus, R. Paniello, W. Thorstad, 2015, Cancer medicine.

Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma

B. Siegel, R. Paniello, W. Thorstad, 2017, Head and Neck Pathology.

Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV-Related Oropharyngeal Squamous Cell Carcinoma.

D. Kallogjeri, W. Thorstad, P. Oppelt, 2023, Otolaryngology Head & Neck Surgery.

Acute Toxicity Profile and Early Efficacy Results of De-Escalated, Risk-Directed Post-Operative Adjuvant Therapy for Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma: A Phase 2 Trial

W. Thorstad, H. Gay, R. Jackson, 2022, International Journal of Radiation Oncology*Biology*Physics.

Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS).

B. Melichar, K. Kern, J. Martini, 2019, Journal of Clinical Oncology.

Dynamic host immune response in virus-associated cancers

Sam Q. Sun, Matthew A. Wyczalkowski, Kimberly J. Johnson, 2019, Communications Biology.

Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Zachary L. Skidmore, Erica K. Barnell, Katie M. Campbell, 2021, Clinical Cancer Research.

A phase I trial of the addition of the CDK 4/6 inhibitor palbociclib to cetuximab in patients with incurable head and neck squamous cell carcinoma (HNSCC).

K. Trinkaus, J. Ley, L. Michel, 2015 .

A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck

K. Trinkaus, B. Siegel, D. Adkins, 2014, Cancer medicine.

Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer

C. Paweletz, D. Kallogjeri, J. Piccirillo, 2023, Science Immunology.

Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.

P. Oppelt, J. Ley, Jingxia Liu, 2023, Journal of Clinical Oncology.

R. Paniello, W. Thorstad, H. Gay, 2021, Medical Oncology.

Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.

J. Ley, P. Oppelt, D. Adkins, 2024, The Lancet. Oncology.